Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

20072,219 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 370, Issue 9605, pp. 2103-2111

Field-Weighted Citation Impact: 147.45